Search Results
Mar 03, 2026, 16:05 ET Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
In Q4 2025, five Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Post quarter-end, two additional BLA filings have occurred. During the fourth quarter, Cryoport's customer, Fondazione Telethon received
More news about: Cryoport, Inc.
Mar 03, 2026, 09:00 ET Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
The European Medicines Agency (EMA) has also provided acceptability of the U.S.-based trial for submission of a Marketing Authorization Application (MAA)."With enrollment complete for OCU400, we enter into a very significant time as a Company," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder
More news about: Market News Updates
Mar 03, 2026, 05:46 ET Asieris' CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
company is advancing research towards an HPV clearance indication for CEVIRA®.For international markets, the marketing authorization application (MAA) for CEVIRA® was accepted for review by the European Medicines Agency (EMA) in February this year. The company has also reached an agreement with the
More news about: Asieris
Mar 03, 2026, 04:55 ET Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
NCT04484415.For international markets, the marketing authorization application (MAA) for Cevira was accepted for review by the European Medicines Agency (EMA) in February this year. The company has also reached an agreement with the
More news about: Photocure
Mar 03, 2026, 04:52 ET Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
NCT04484415.For international markets, the marketing authorization application (MAA) for Cevira was accepted for review by the European Medicines Agency (EMA) in February this year. The company has also reached an agreement with the
More news about: Photocure
Mar 02, 2026, 16:15 ET MAA Announces Regular Quarterly Preferred Dividend
About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
Feb 27, 2026, 16:15 ET MAA to Participate in the 2026 Citi Global Property CEO Conference
https://kvgo.com/citi/maa-march-2026.The webcast replay will be available on the "For Investors" page of MAA's website after the conclusion of the live event. About MAAMAA is a self-administered real estate investment trust
More news about: MAA
Feb 27, 2026, 05:03 ET Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira® (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) has been accepted by the European Medicines
More news about: Photocure
Feb 25, 2026, 17:28 ET MAA Announces Pricing of Senior Unsecured Notes Offering
GERMANTOWN, Tenn., Feb. 25, 2026 /PRNewswire/ -- Mid-America Apartment Communities, Inc., ("MAA") (NYSE: MAA) today announced that its operating partnership, Mid-America Apartments, L.P. ("MAALP"), priced a $200,000,000 offering of MAALP's 4.650% senior
More news about: MAA
Feb 16, 2026, 08:01 ET Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details
More news about: Acurx Pharmaceuticals, Inc.
Feb 09, 2026, 14:35 ET TEAMSTERS ATTORNEYS WIN JUST CAUSE PROTECTIONS
Feb. 9, 2026 /PRNewswire/ -- For the first time, hundreds of attorneys with the San Francisco Municipal Attorneys Association (MAA) and members of Teamsters Local 856 have won just cause job protections through arbitration.
More news about: Teamsters Local 856
Feb 04, 2026, 16:15 ET MAA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
2026. During the fourth quarter of 2025, MAA completed the lease-up of MAA Vale located in Raleigh, North Carolina. Balance Sheet and Financing ActivitiesAs of December 31, 2025, MAA had $879.2 million of combined cash and available capacity under MAALP's
More news about: MAA
Jan 29, 2026, 17:08 ET THE OLYMPIC TRUCE STARTS FRIDAY JANUARY 30
patterns."We're not interested in naming and shaming—we're interested in providing real transparency and a spur to accountability," explained MAA Managing Director Daniel Wagner. "Our own methodology is transparent, our data is verifiable, and our goal is simple: make it impossible to ignore when
More news about: Truce Foundation
Jan 23, 2026, 08:00 ET CUISINE SOLUTIONS® CELEBRATES 9TH ANNUAL INTERNATIONAL SOUS VIDE DAY
highlighting the technique's enduring influence on modern cooking.Bangkok – January 30, 2026 | BAR.YARD at Kimpton Maa-Lai BangkokHome to one of Cuisine Solutions' state-of-the-art facilities, Bangkok will conclude the celebrations, showcasing how precision and
More news about: Cuisine Solutions
Jan 20, 2026, 17:10 ET MAA Announces Taxable Composition of 2025 Distributions
specific tax treatment of these MAA distributions. The company is releasing information at this time to aid those required to distribute Forms 1099 on the company's dividends. No material change in the taxable composition is expected.About MAAMAA, an S&P 500 company, is a self-administered
More news about: MAA
Jan 14, 2026, 16:15 ET MAA Announces Date of Fourth Quarter and Full-Year 2025 Earnings Release, Conference Call
GERMANTOWN, Tenn., Jan. 14, 2026 /PRNewswire/ -- MAA (NYSE: MAA) announced today that the Company expects to release its fourth quarter and full-year 2025 results on Wednesday, February 4, 2026, after market close and
More news about: MAA
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation." On this news, Anavex's stock price fell $2.05 per share, or 35.94%, to close at $3.65
More news about: Pomerantz LLP
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation." On this news, Anavex's stock price fell $2.05 per share, or 35.94%, to close at $3.65
More news about: Pomerantz LLP
Dec 17, 2025, 16:15 ET MAA Announces Increase to Quarterly Common Dividend
consecutive year MAA has increased its dividend to shareholders.As established in prior quarters, the board of directors declared the quarterly common dividend in advance of MAA's earnings announcement that is expected to be made on February 4, 2026.About MAAMAA is a self-administered
More news about: MAA
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation." On this news, Anavex's stock price fell $2.05 per share, or 35.94%, to close at $3.65
More news about: Pomerantz LLP
Dec 02, 2025, 10:30 ET AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)
AOBiome already plans to implement in its study designs.This agreement will allow AOBiome to file the initial Market Authorization Application (MAA) to the EMA based on the outcomes of the 2 pivotal and 1 open-label extension (OLE) studies in adolescents and adults as currently planned and endorsed
More news about: AOBiome Therapeutics
Dec 01, 2025, 16:15 ET MAA Announces Regular Quarterly Preferred Dividend
About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
Nov 25, 2025, 08:30 ET Rexford Industrial Appoints David Stockert to Board of Directors
Post Properties merged with Mid-America Apartment Communities, Inc. (NYSE: MAA). Mr. Stockert joined Post Properties in 2001 as President and Chief Operating Officer. Mr. Stockert continues to serve on the Board of Directors of MAA. Between 1995 and 2000, Mr. Stockert held senior leadership roles at Duke
More news about: Rexford Industrial Realty, Inc.
Nov 24, 2025, 17:31 ET Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
Bowel Syndrome MarketIn June 2025, Zealand Pharma announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for glepaglutide for the treatment of adult patients with SBS. In April 2025, Napo Pharmaceuticals
More news about: DelveInsight Business Research, LLP
Nov 20, 2025, 14:58 ET Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.